🦋 SIGNATURE DESK // BUTTERFLY RIPPLE ENGINE
Mara Quenwick | Roarable AI Analyst
The Interactive Butterfly Map: Multi-Tier Supply Chains & Second-Order Bottlenecks
“Who else gets paid, squeezed, or left behind if this happens?” Click any ecosystem or anchor ticker below to inspect primary-source Form 10-K/20-F customer disclosures (solid glowing lines) alongside second-order economic bottlenecks and squeezed losers (dashed lines)—with zero invented revenue percentages.
48
Mapped Links
40
10-K Confirmed
6 Chains
8 Hypotheses
ENTRY MODE:
SELECT ECOSYSTEM SUPPLY CHAIN (48 VERIFIED MULTI-TIER CONNECTIONS)
ANCHOR HUBS:
FILTER EDGES:
MULTI-TIER RIPPLE CHAIN // ANCHOR: LLY
LLY (Eli Lilly and Company) — 1st & 2nd Order Supply-Chain Ripple Map
Solid Glow = CONFIRMED FILING (10-K / 20-F / Contract)Dashed = ANALYST HYPOTHESIS (2nd-Order Mechanism)TailwindHeadwindMixed / Bottleneck
NODE SELECTED: LLYEli Lilly and Company• Highlighting 1st & 2nd-order transmission chain
Synchronized Transmission Matrix (9 Connections)
CLICK ANY ROW TO INSPECT PRIMARY FILING EVIDENCE →| Chain (Source → Target) | Relationship | Evidence Tier | Effect | Materiality / Disclosed Share |
|---|---|---|---|---|
| WST→LLY | DIRECT SUPPLIER | ✓ CONFIRMED FILING | TAILWIND | Undisclosed % — Disclosed GLP-1 Biologics Elastomer & Auto-Injector Component Driver (WST Form 10-K) |
| TMO→LLY | BOTTLENECK BENEFICIARY | ✓ CONFIRMED FILING | TAILWIND | Undisclosed % — Sterile Fill-Finish CDMO Scarcity Beneficiary Post-Catalent Acquisition (TMO Form 10-K) |
| LLY→NVO | SUBSTITUTE / RIVAL | ✓ CONFIRMED FILING | HEADWIND | Direct Duopoly Competition — GLP-1 Franchise Represents >55% of Novo Nordisk Revenue (NVO Form 20-F) |
| LLY→CVS | CONFIRMED CUSTOMER | ✓ CONFIRMED FILING | MIXED / CONSTRAINT | Undisclosed % — Disclosed GLP-1 Script Volume Lift vs. Retail Reimbursement Squeeze (CVS Form 10-K) |
| LLY→UNH | POLICY / BUDGET LINK | ✓ CONFIRMED FILING | HEADWIND | Undisclosed % — Disclosed Specialty Pharmacy Utilization & Medical Care Ratio Pressure (UNH Form 10-K) |
| LLY→RMD | POTENTIAL LOSER | ◇ ANALYST HYPOTHESIS | HEADWIND | Second-Order Clinical Substitute vs. Patient-Funnel Debate (Undisclosed %; Cited in RMD Form 10-K) |
| LLY→DXCM | BOTTLENECK BENEFICIARY | ◇ ANALYST HYPOTHESIS | MIXED / CONSTRAINT | Second-Order Metabolic Companion Prescription Dynamic (Undisclosed %; Cited in DXCM Filings) |
| NVO→ISRG | POTENTIAL LOSER | ✓ CONFIRMED FILING | MIXED / CONSTRAINT | ~3%–4% Bariatric Procedure Mix Headwind Explicitly Cited by Management (ISRG Form 10-K Item 7) |
| DHR→NVO | DIRECT SUPPLIER | ◇ ANALYST HYPOTHESIS | TAILWIND | Second-Order Bioprocessing Chromatography & Filtration Exposure (Undisclosed %) |